Denisse Rojas Marquez, MD, MPP and Hazel Lever, MD, MPH
“Very important persons” care contributes to multitiered, racially segregated health service delivery streams that influence clinicians’ conceptions of what patients deserve from them.
AMA J Ethics. 2023;25(1):E66-71. doi:
10.1001/amajethics.2023.66.
Kimberly A. Singletary, PhD and Marshall H. Chin, MD, MPH
The Roadmap to Advance Health Equity offers specific, actionable antiracist payment reform strategies to help ensure that everyone can receive good health services and optimize their health.
AMA J Ethics. 2023;25(1):E55-65. doi:
10.1001/amajethics.2023.55.
Despite a tendency to react otherwise, there is no obvious reason to believe that economically disadvantaged people ought not to be exposed to the same levels of research risk as the rest of the population.
The AAP’s guidelines on lipid screening for children raise concerns about the fundamental purpose of prevention and its role in balancing individual autonomy with the benefits of society at large.
Physician behavior that generates a patient complaint and ultimately leads to disciplinary action is both legally and ethically problematic—violating both regulatory rules and professional codes.
AMA J Ethics. 2015;17(5):448-455. doi:
10.1001/journalofethics.2015.17.5.pfor1-1505.
Research in the PED and PICU is essential to medical understanding of the efficacy of emergency interventions. Researchers must minimize the additional stress that consent and participation in research entail for pediatric patients and their families.
Anne Drapkin Lyerly, MD, MA and Ruth R. Faden, PhD, MPH
Participation in a research study—in which there are rigorous standards and close monitoring—may be a safer context for the use of medications in pregnancy than the clinical setting, where the evidence base is lacking.
This process of developing EBM-based guidelines and applying them to clinical care highlights the tension between generating unbiased knowledge based on statistical aggregation and the application of this information to individual patients.
Elderly persons should not be excluded from participation in clinical trials for cardiovascular drugs since that population comprises the largest number of patients with cardiovascular disease.
The FDA's decision to put a black-box warning on antidepressant labels may be misleading because it implies that antidepressants have definitely been found to increase suicidality in adolescents, when in fact there is merely a lack of clear evidence about their safety.